Holen Sie sich die Stockscreener-App
748.72
1.06%
-8.04
Vorhandelsmarkt:
757.80
9.08
+1.21%
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month - GlobeNewswire Inc.
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
Earnings call transcript: Argenx Q4 2025 sees strong earnings beat, stock dips - Investing.com
BofA raises argenx stock price target to $1,013 on trial success - Investing.com
Stifel cuts argenx stock price target to $1,227 on valuation - Investing.com
ARGENX : Gets a Buy rating from Goldman Sachs - marketscreener.com
Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial - marketscreener.com
ARGENX : Receives a Buy rating from Bernstein - marketscreener.com
argenx ADR earnings beat by $2.07, revenue topped estimates - Investing.com
Argenx SE FY25 swings to profit as Vyvgart sales double - Investing.com
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Argenx Reports Higher FY25 Attributable Profit, Operating Income - marketscreener.com
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Insights into argenx's Upcoming Earnings - Sahm
Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART - Insider Monkey
argenx to Present at TD Cowen 46th Annual Healthcare Conference - ChartMill
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Finviz
Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 - Insider Monkey
Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth - Finviz
Wells Fargo analyst sees potential in Argenx SE’s (ARGX) Vyvgart, increases PT to $1,317 - MSN
Goldman Sachs Assumes Penguin Solutions (PENG) Coverage with Buy Rating, $25 PT - Yahoo Finance
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Insider Monkey
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Yahoo Finance
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds - Yahoo Finance
Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW) - Yahoo Finance
Assessing argenx (ENXTBR:ARGX) Valuation After Recent Share Price Pullback - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Vyvgart Priority Review Puts Argenx Valuation Gap And Pipeline In Focus - Yahoo Finance
Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Finviz
Argenx’s (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Yahoo Finance
Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317 - Finviz
argenx SE (ARGX): A Bull Case Theory - Finviz
Why Argenx SE (ARGX) Stock Advanced on Commercial Execution - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Jefferies Keeps Their Buy Rating on Argenx Se (ARGX) - The Globe and Mail
Argenx shares rise as FDA reviews Vyvgart for broader use By Investing.com - Investing.com South Africa
Argenx shares rise as FDA reviews Vyvgart for broader use - Investing.com
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - Sahm
William Blair reiterates Outperform rating on argenx stock - Investing.com
Argenx shares slip as Q4 results come in broadly in line By Investing.com - Investing.com South Africa
Argenx shares slip as Q4 results come in broadly in line - Investing.com
Wells Fargo Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
argenx SE stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Argenx SE Announces CEO Changes - marketscreener.com
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Argenx stock holds steady as TD Cowen reiterates Buy rating By Investing.com - Investing.com South Africa
Argenx stock holds steady as TD Cowen reiterates Buy rating - Investing.com
Argenx founder Tim Hauwermeiren to step down as CEO; Karen Massey named successor - Investing.com India
argenx Announces Leadership Transition Marking Next Evolution of Growth - Sahm
1.97%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):